Our doctors believe that participating in research is the best way to ensure that our patients
receive the best care and gain access to the latest treatment for their condition. Our doctors
attend and present at conferences in Europe and USA several times every year.
Below we list videos and a selection of articles published by our doctors in international
over the past three years.
Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma. The New
England Journal of Medicine. 2019.
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to
ibrutinib plus venetoclax in mantle cell lymphoma. Nature Medicine. 2019.
Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin
lymphoma. Clinical Advances in Haematology and Oncology. 2019.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
New England Journal of Medicine. 2019.
Considerations for pre-transfusion immunohaematology testing in patients receiving
anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Internal Medicine Journal. 2018.
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly
and relapsed multiple myeloma. Scientific Reports. 2018.
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve
with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
American Journal of Hematology. 2018.
Extended follow-up and impact of high-risk prognostic factors from the phase 3
study in patients with previously treated CLL/SLL. Leukemia. 2018.
Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. New England
Journal of Medicine. 2018.
Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era
targeted therapies. Blood Reviews. 2018.
Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1
antibody for waldenström macroglobulinemia. Haematologica. 2018.
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts
survival of chronic lymphocytic leukaemia patients treated with fludarabine,
cyclophosphamide and rituximab. British Journal of Haematology. 2018.
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for
vulnerable patients with relapsed refractory multiple myeloma: final analysis of the
phase II RevLite study. British Journal of Haematology. 2017.
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma
end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer
Chemother Pharmacol 2017.
Novel dose optimization strategies in patients with newly diagnosed chronic myeloid
leukemia in chronic phase treated with nilotinib: final results from the ENESTxtnd
study. British Journal of Haematology. 2017.
Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
Internal Medicine Journal. 2017
Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of
Annals of oncology : official journal of the European Society for Medical Oncology.
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leukemia and
Central nervous system immune reconstitution inflammatory syndrome after ibrutinib
therapy for Richter transformation. Leukemia and Lymphoma. 2017.
Circulating tumour DNA reflects treatment response and clonal evolution in chronic
lymphocytic leukaemia. Nature Communications. 2017.
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor
venetoclax. Blood. 2017.
Consensus guidelines for the diagnosis and management of patients with classic hairy
leukemia. Blood. 2017.
Dancing partners at the ball: Rational selection of next generation anti-CD20
for combination therapy of chronic lymphocytic leukemia in the novel agents era.
Factors predicting the identification of new organisms in follow-up blood cultures
during episodes of neutropenic sepsis. British Journal of Haematology. 2017.
FDG PET in follicular lymphoma: more than a staging test? Leukemia and Lymphoma.
High-dose therapy and autologous stem cell transplantation may only be applicable to
selected patients with secondary CNS diffuse large B-cell lymphoma. British
of Haematology. 2017.
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia
(iNNOVATE): an open-label substudy of an international, multicentre, phase 3
The Lancet Oncology. 2017.
Ibrutinib may impair serological responses to influenza vaccination.
Ibrutinib monotherapy as effective treatment of central nervous system involvement by
chronic lymphocytic leukaemia. British Journal of Haematology. 2017.
Management of high risk chronic lymphocytic leukaemia (CLL) patients in
Internal Medicine Journal. 2017.
Management of patients with previously untreated chronic lymphocytic leukaemia with
obinutuzumab and chlorambucil. Internal Medicine Journal. 2017.
Microvesicles in chronic lymphocytic leukemia: ready for prime time in the
Leukemia and Lymphoma. 2017.
Novel agents versus chemotherapy as frontline treatment of CLL. Leukemia and
Plasmablastic Richter transformation as a resistance mechanism for chronic
leukaemia treated with BCR signalling inhibitors. British Journal of
Practical recommendations for the choice of anticoagulants in the management of
with atrial fibrillation on ibrutinib. Leukemia and Lymphoma. 2017.
The positive effect of deferasirox on erythropoiesis in a patient with a dual
of myelofibrosis and diffuse large B-cell lymphoma. Leukemia and Lymphoma. 2017.
Treatment of patients with Waldenström macroglobulinaemia: clinical practice
from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Internal Medicine Journal. 2017.
Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents.
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia
treated with single-agent ibrutinib. British Journal of Haematology. 2017.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a
phase 1b study. The Lancet Oncology. 2017.